Paraneoplastic cerebellar degeneration (PCD) is one of the most common paraneoplastic neurological syndromes characterized by the rapid development of severe cerebellar ataxia. In this report, a 23-year-old female with noticeable dizziness and gait instability was described. The enhanced CT scanning suggested the presence of a pelvic tumor. Then, PCD was established. Postoperative pathological result defined it as a liposarcoma (LS) with dedifferentiation. Interestingly, clinical symptoms disappeared after the surgical removal of the pelvic tumor. To our knowledge, this was the first case report with PCD due to LS.

Keywords:
Liposarcoma, Paraneoplastic, Pelvic
1.
Sioka C, Fotopoulos A, Kyritsis AP: Paraneoplastic neurological syndromes and the role of PET imaging. Oncology 2010;78:150-156.
2.
Darnell RB, Posner JB: Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003;349:1543-1554.
3.
Porto L, Miranda M, Gomes A, Andre R, Rodrigues B: Paraneoplastic neurological syndrome as an initial indicator of small cell carcinoma of the lung. BMJ Case Rep 2013;2013:pii:bcr2012008432.
4.
Rana AQ, Rana AN, Adlul A: Acute ataxia due to anti-Yo antibody paraneoplastic cerebellar degeneration 4 months prior to diagnosis of uterine carcinoma. Acta Neurol Belg 2012;112:303-304.
5.
Finsterer J, Voigtlander T, Grisold W: Deterioration of anti-Yo-associated paraneoplastic cerebellar degeneration. J Neurol Sci 2011;308:139-141.
6.
O'Brien TJ, Pasaliaris B, D'Apice A, Byrne E: Anti-Yo positive paraneoplastic cerebellar degeneration: a report of three cases and review of the literature. J Clin Neurosci 1995;2:316-320.
7.
Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R: Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-1140.
8.
Zhu Y, Chen S, Chen S, Song J, Chen F, Guo H, Shang Z, Wang Y, Zhou C, Shi B: An uncommon manifestation of paraneoplastic cerebellar degeneration in a patient with high grade urothelial, carcinoma with squamous differentiation: a case report and literature review. BMC Cancer 2016;16:324.
9.
Kollar A, Benson C: Current management options for liposarcoma and challenges for the future. Expert Rev Anticancer Ther 2014;14:297-306.
10.
Dodd LG: Update on liposarcoma: a review for cytopathologists. Diagn Cytopathol 2012;40:1122-1131.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.